Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fox

Showing results (81-90 of 186) with videos related to

Pageof 19
Sort By:
Cancer Medicine|January 16, 2023
Changing incentives to ACCELERATE drug development for paediatric cancerTeresa de Rojas, Pamela Kearns, Patricia Blanc, et al.
Pediatric Blood & Cancer|September 5, 2009
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroHolly J Meany, Dan L Sackett, John M Maris, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
JMIR Public Health and Surveillance|May 27, 2016
An Integrated Service Delivery Model to Identify Persons Living with HIV and to Provide Linkage to HIV Treatment and Care in Prioritized Neighborhoods: A Geotargeted, Program Outcome StudyPaula M Frew, Matthew Archibald, Jay Schamel, et al.
The Oncologist|July 1, 2008
Characteristics and outcome of pediatric patients enrolled in phase I oncology trialsAerang Kim, Elizabeth Fox, Katherine Warren, et al.
Pediatric Blood & Cancer|April 28, 2017
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)James I Geller, John P Perentesis, Xiaowei Liu, et al.
Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412Kara L Davis, Elizabeth Fox, Emasenyie Isikwei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2017
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group StudyYael P Mossé, Stephan D Voss, Megan S Lim, et al.
Cancer Chemotherapy and Pharmacology|August 21, 2010
Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate modelMeredith K Chuk, Diane E Cole, Cynthia McCully, et al.
Pageof 19

Showing results (81-90 of 186) with videos related to

Sort By:
Pageof 19
Cancer Medicine|January 16, 2023
Changing incentives to ACCELERATE drug development for paediatric cancerTeresa de Rojas, Pamela Kearns, Patricia Blanc, et al.
Pediatric Blood & Cancer|September 5, 2009
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroHolly J Meany, Dan L Sackett, John M Maris, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
JMIR Public Health and Surveillance|May 27, 2016
An Integrated Service Delivery Model to Identify Persons Living with HIV and to Provide Linkage to HIV Treatment and Care in Prioritized Neighborhoods: A Geotargeted, Program Outcome StudyPaula M Frew, Matthew Archibald, Jay Schamel, et al.
The Oncologist|July 1, 2008
Characteristics and outcome of pediatric patients enrolled in phase I oncology trialsAerang Kim, Elizabeth Fox, Katherine Warren, et al.
Pediatric Blood & Cancer|April 28, 2017
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)James I Geller, John P Perentesis, Xiaowei Liu, et al.
Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412Kara L Davis, Elizabeth Fox, Emasenyie Isikwei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2017
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group StudyYael P Mossé, Stephan D Voss, Megan S Lim, et al.
Cancer Chemotherapy and Pharmacology|August 21, 2010
Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate modelMeredith K Chuk, Diane E Cole, Cynthia McCully, et al.
Pageof 19